Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 29650362

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 May
First author
Italiano A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 May;19(5):586-587. doi: 10.1016/S1470-2045(18)30149-9.
    note
    Source null
    related pmid
    29650364
    relationship
    Comment in

Authors and identifiers

  1. name
    Italiano A
    type
    Author
  2. name
    Soria JC
    type
    Author
  3. name
    Toulmonde M
    type
    Author
  4. name
    Michot JM
    type
    Author
  5. name
    Lucchesi C
    type
    Author
  6. name
    Varga A
    type
    Author
  7. name
    Coindre JM
    type
    Author
  8. name
    Blakemore SJ
    type
    Author
  9. name
    Clawson A
    type
    Author
  10. name
    Suttle B
    type
    Author
  11. name
    McDonald AA
    type
    Author
  12. name
    Woodruff M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Italiano A
    type
    Author
  2. name
    Soria JC
    type
    Author
  3. name
    Toulmonde M
    type
    Author
  4. name
    Michot JM
    type
    Author
  5. name
    Lucchesi C
    type
    Author
  6. name
    Varga A
    type
    Author
  7. name
    Coindre JM
    type
    Author
  8. name
    Blakemore SJ
    type
    Author
  9. name
    Clawson A
    type
    Author
  10. name
    Suttle B
    type
    Author
  11. name
    McDonald AA
    type
    Author
  12. name
    Woodruff M
    type
    Author
bibliography ids
  1. nci-bib-4e4a6339cd29dad3cba804cb
book metadata
content sha256
6cd8be288c36f245a61fc879a9c04448ab2c143208ef79d57fb23a86b8ef9da4
document type
citation
dois
  1. 10.1016/S1470-2045(18)30145-1
electronic publication date
display
2018 Apr 9
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29650362
immutable id
pubmed:29650362@6cd8be288c36f245a61fc879a9c04448ab2c143208ef79d57fb23a86b8ef9da4
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
5
name
The Lancet. Oncology
nlm unique id
100957246
pages
649-659
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 May;19(5):586-587. doi: 10.1016/S1470-2045(18)30149-9.
    note
    Source null
    related pmid
    29650364
    relationship
    Comment in
outcomes validated
false
pmid
29650362
provenance
batch id
c4c0356d060413f719c2
provider
NCBI PubMed ESummary
record sha256
ed537841f7ba061d3a2f4c3b6e0cd544b1bec614234c62be8b72d4884f84566c
response sha256
adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
retrieved at
2026-09-09T23:47:33.674758+00:00
publication date
display
2018 May
precision
month
year
2018
publication types
  1. Clinical Trial, Phase I
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29650362/
title
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

Preserved source evidence · Independent clinical review pending · Not medical advice